Stem Cells in The Treatment of Infertility

Premature infants with stem cell ovarian failure (POF) for infertility occur in 75% of women under the age of 40, with primary or secondary gonadotropic hormone amenorrhea, and estrogen deficiency. Primary amenorrheic women do not ovulate or have been reported not to be pregnant in their own oocytes, but more than one third of the women are pregnant at least once before the high promotion POF occurs It is. The lack of follicle turnover is due to age-related failure of certain memory cells in the lymphatic system and bone marrow, which is required for the production of effector cells to migrate to the ovary and promote the transformation of OSE cells It is conceivable.

Infertility treatment is the most valuable source of embryos and India lacks clear legislation on artificial reproductive technology (ART). Existing guidelines for leading stem cell research including embryonic stem cells were developed by the Indian Medical Research Council (ICMR). Clear enactment will help strengthen ART clinic activities by strengthening strict accountability and accountability by criminal provision. Registration of the ART clinic is mandatory and should be monitored on a regular basis to ensure that they provide high levels of care, care, treatment quality and equipment, especially in terms of embryo use, disposal and preservation .

Article 1: Authorized sources of pluripotent stem cells are: 1) additional embryos from in vitro fertilization treatment plan (infertility treatment only), 2) aborted embryos, 3) embryos from induction of test treatment simulation, 4) IP, 5) delivery of newborn umbilical cord blood or placenta

Summary and Ethical Recommendations on Ethical Considerations in Iran's Stem Cell Research: Review

The source of stem cells has made ethics more complicated. Stem cells can be obtained from one of three methods. Embryos produced during infertility treatment are sometimes called "replacement embryos". If they are needed again for pregnancy, they usually freeze at a very low temperature. The second source is an embryo created by manually fertilizing ova with sperm provided for laboratory use. The third one is a fetus or a miscarriage from an organ. These seem to be limited to the types of organizations they can develop. Unfortunately, this has deleterious side effects on the patient. The organ proliferated from stem cells of one of the above sources will have foreign DNA that is inconsistent with the organ receptor DNA. Recipients are forced to take anti-rejection drugs in the rest of their lives and can reject organs at any time.